Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amag drug found effective in treatment of chronic kidney disease
Patients received either two doses of 510 mg of intravenous (IV) ferumoxytol within one week or 200 mg of oral iron daily for three weeks and were followed
Patients received either two doses of 510 mg of intravenous (IV) ferumoxytol within one week or 200 mg of oral iron daily for three weeks and were followed
Preliminary data from the pilot study suggests repeat administration with Inno-305 is well tolerated and immune response can be elicited following three vaccinations. In the study conducted at
The new agreement provides unlimited access to Amerinet’s national portfolio of product and service contracts and proprietary Total Spend Management tools designed to ensure health care providers maximize
The MAA for dapoxetine was submitted under the decentralized procedure, in which Sweden will act as the reference member state and Austria, Finland, Germany, Italy, Portugal and Spain
The Phase I trial is a multi-center, open-label, sequential dose-escalation study that will enroll 20-40 patients with relapsed or refractory acute myeloid leukemia (AML). The preliminary clinical data
In the Activate Phase IIa study, CDX-110 treated Glioblastoma Multiforme (GBM) patients showed a median survival time of 30 months, more than a 100% increase in survival, versus
This open label dose escalation safety study will consist of two parts. In part I, 26 to 62 patients will be enrolled depending on the number of dose
The Phase I study was designed to assess the safety of AVE9633 when administered on days 1 and 8 of a 28-day cycle. Increasing doses of the compound
Under the agreement, Pharmetics will acquire the assets, including equipment, facilities and land, at Patheon’s facilities in Fort Erie and Burlington in Ontario. Pharmetics will provide employment to
In addition to safety and tolerability assessment, Nventa will also collect immunological data from these patients at the end of each cohort that may provide an early indication